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A B S T R A C T   
Under those pathological conditions in which Myoglobin and Hemoglobin escape their cellular environments and 
are thus separated from cellular reductive/protective systems, the inherent peroxidase activities of these proteins 
can be expressed. This activity leads to the formation of the highly oxidizing oxo-ferryl species. Evidence that this 
happens in vivo is provided by the formation of a covalent bond between the heme group and the protein and this 
acts as an unambiguous biomarker for the presence of the oxo ferryl form. The peroxidatic activity also leads to 
the oxidation of lipids, the products of which can be powerful vasoconstrictive agents (e.g. isoprostanes, neu-
roprostanes). Here we review the evidence that lipid oxidation occurs following rhabdomyolysis and sub- 
arachnoid hemorrhage and that the products formed from arachidonic acid chains of phospholipids lead, 
through vasoconstriction, to kidney failure and brain vasospasm. Intervention in these pathological conditions 
through administration of reducing agents to remove ferryl heme is discussed. Through-protein electron transfer 
pathways that facilitate ferryl reduction at low reductant concentration have been identified. We conclude with 
consideration of the therapeutic use of Hemoglobin Based Oxygen carriers and how the toxicity of these may be 
reduced by engineering such electron transfer pathways into hemoglobin.   
1. Introduction 
When I (MTW) arrived in Rome in February 1971 as a postdoctoral 
fellow I knew very little about myoglobin (Mb) or hemoglobin (Hb). I 
was working on the cytochromes so, although familiar with heme pro-
teins, I was not well acquainted with the globin family. The laboratory 
(Istituto di Chimica Biologica) in Rome was a world leader in the study 
of Hb and Mb so I found myself surrounded by experts in the field, 
including many visitors from all around the world who flocked to work 
in Rome. How fortunate for me to have had the opportunity to learn so 
much in such a short time and from teachers as eminent as Eraldo 
Antonini and Maurizio Brunori. The time I spent in Rome was the 
happiest of my scientific career and it was when I really learnt how to do 
experimental research. In the summer of 1971, there was a buzz of 
excitement in the laboratory heralding the arrival of the first copy of 
“The Book” (Antonini and Brunori, 1971) I remember how impressed I 
was that such a wealth of knowledge could be compiled and the 
experimental aspects so well integrated with the theoretical. 
Following my fellowship in Rome I returned to the UK and somewhat 
later developed an interest in the properties of Hb and Mb and “The 
Book” has been ever present in my laboratory and until the present it is 
still frequently consulted. It is still considered as the Bible for Mb and Hb 
biochemistry. 
This review is concerned with an aspect of the biochemistry of Mb 
and Hb that did not, however, feature in The Book because there the 
emphasis was on the physiological roles of Mb and Hb rather than the 
pathophysiology of these proteins. Here we consider the deleterious 
peroxidatic effects of Mb and Hb that become apparent when these 
proteins are released from their cellular environments i.e. the myocytes 
and the erythrocytes and enter the tissues of the organism. When 
enclosed in their cells the hemes are maintained in the ferrous state that 
is a requirement for them to act as oxygen storage or transport proteins, 
as oxygen has affinity for and bind only to this state to form oxy com-
plexes. Furthermore, these cells contain a range of antioxidant defense 
mechanisms that protect them from oxidative damage. A problem arises 
however once the heme proteins escape their cellular compartments and 
enter spaces that lack reductive and defense systems. This problem stems 
from the oxidation of the heme oxy complexes by the bound oxygen 
(autoxidation) that can no longer be reversed by reduction within the 
cell. The product of autoxidation are ferric heme (Fe3+) Hb or Mb and 
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the superoxide anion, that may dismute to generate hydrogen peroxide 
(Eq (1))  
(Fe2+O2)Hb/Mb > (Fe3+)Hb/Mb + O2•- and 2H+ + 2O2•- > H2O2       Eq 1 
It is the further reaction between the ferric protein and H2O2, 
generated either from the autoxidation reaction or from macrophage 
activity that initiates peroxidatic activity and tissue damage. Eq 2  
(Fe3+)Hb/Mb + H2O2 > (Fe4+=O2− )•+Hb/Mb                                   Eq2 
The product of this reaction is an oxyferryl heme iron and a radical 
cation that quickly migrates to a residue on the protein forming 
(Fe4+=O2− )•+R. This may then deprotonate to yield the species 
(Fe4+=O2− )•R, the neutral radical which is EPR detectable, It is the 
consequences of the formation, within the tissues, of these highly 
oxidizing ferryl and ferryl-induced radical species that is the subject of 
this review. 
2. Evidence that the oxyferryl radical cation is formed in vivo 
Giulivi and Davies reported the presence of a ferryl heme species in 
human red blood cells exposed to a steady flux of H2O2, showing that the 
anti-oxidant systems of the cell could be overwhelmed (Giulivi and 
Davies, 1994). That this can happen under normal conditions within 
humans was demonstrated by Svistunenko et al. (1997). In this study 
samples of venous blood from healthy adults were drawn, frozen and 
examined by EPR spectroscopy. The EPR spectra clearly showed the 
presence of a protein based radical at ~1 μM concentration. This radical 
was identical in line-shape and power saturation behavior to that 
generated in vitro through the reaction of Fe(III)Hb (metHb) with H2O2. 
Additionally, chromatographic and mass spectroscopic analysis of Hb 
showed that an oxidatively modified chlorin product of heme can be 
detected in healthy adults and that this can significantly increase during 
acute oxidative stress (Vollaard et al., 2005). These studies demonstrate 
that even within the protective environment of the red blood cells and 
the plasma sufficient peroxide and metHb are present to react and yield 
the characteristic EPR protein radical signal, oxidative damage to the 
heme and by implication the oxyferryl species. 
The evidence for the occurrence of the oxyferryl species and radical 
in animal and human disease states, such as acute kidney dysfunction 
(previously called acute renal failure) following rhabdomyolysis, is very 
strong as there is a biomarker that unequivocally proves that these ox-
idants are formed under conditions in which the proteins escape their 
cellular environments. Rhabdomyolysis is a condition in which Mb is 
released from myocytes either through mechanical injury (crush injury) 
or chemical/drug induced lysis of muscle cells (Briner et al., 1986; 
Bywaters and Beall, 1941). In humans crush injury often results from 
earthquakes, exposure to explosions, e.g. bombing campaigns, and it can 
also be a consequence of drug overuse, intensive exercise, etc (Atef--
Zafarmand and Fadem, 2003; Hampel et al., 1983; Nepali et al., 2017; 
Sinert et al., 1994; Su et al., 2009). A distinctive feature of rhabdo-
myolysis is that patients who survive the initial mechanical trauma and 
begin to heal then succumb to kidney failure some days later. The urine 
of these patients is coloured by myoglobin, released from myocytes, and 
as a molecule with MWt of 17000 Da it passes through the kidney into 
the post glomerular space and then to the bladder. Examination of this 
Mb shows that in transit it has undergone a remarkable transformation. 
In its native state within the myocyte the heme and protein constituents 
of holo-myoglobin are not connected to each other through a covalent 
bond and may easily be separated at acid pH using organic solvents that 
dissolve the heme (Antonini and Brunori, 1971; De Duve, 1948). A 
significant fraction of the myoglobin recovered from the urine is how-
ever radically altered, namely the heme and protein are covalently 
linked and cannot be separated by HPLC (Fig. 1) (Holt et al., 1999; 
Reeder et al., 2002a, 2002b). How has this transformation come about? 
In vitro studies have shown that the ferryl species, formed from the re-
action between Fe(III) Mb and H2O2 (Eq (2)), can react further. The 
protonated ferryl species (Fe4+=OH− )•+R may be considered to have 
partly the character (Fe3+=OH•)•+R i.e. a transient ferric-hydroxyl 
radical species. The highly reactive hydroxyl radical, OH•,abstracts a 
hydrogen atom from the porphyrin ring producing a radical on the 
porphyrin that terminates with the radical on the protein to form a co-
valent bond (Reeder et al., 2002b, 2007; Silaghi-Dumitrescu et al., 
2007). Formation of this bond alters the conjugated system of the 
porphyrin converting it to a d type heme with a spectrum different from 
that of the original b type heme. In fact the CO complex of the covalently 
bound heme is bright green (Reeder, 2010). 
The fact that covalent heme-to-protein bonds are formed as a 
consequence of rhabdomyolysis, and that the crosslinked product has 
the same spectral properties as those of the crosslinked protein formed in 
vitro substantiate the view that formation in vivo is through the reaction 
of Fe(III) Mb with H2O2 in the post glomerular space of the kidney, 
where there is no protective anti-oxidant system (Boutaud et al., 2010; 
Holt et al., 1999; Reeder et al., 2002a). Thus, the cross-link between the 
protein and the heme constitutes an unambiguous biomarker for per-
oxidatic activity of the holo-protein. 
Given the above one may enquire whether there are other chemical 
transformations that result from this activity. Examination of the urine 
Fig. 1. Reverse-phase HPLC of myoglobin (red line) 
and oxidatively modified myoglobin (blue line). 
Myoglobin shows heme B (~14.7 min) and apoMb 
(22.1 min) only. Peroxide-damaged Mb shows 
additional oxidatively modified hemes (7–14 min) 
and a heme that is covalently attached to the globin 
(peak maximum 23.7 min). Inset: HPLC optical 
spectra of unmodified heme (A, red) oxidatively 
modified ‘d-type’ free heme (B, blue) and covalently 
bound cross-linked heme (C, green). Spectra are 
offset for clarity. (For interpretation of the refer-
ences to colour in this figure legend, the reader is 
referred to the Web version of this article.)   
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of human patients suffering from rhabdomyolysis and rat models of this 
condition revealed the presence of a range of lipid oxidation products 
(Boutaud et al., 2010; Gois et al., 2016; Holt et al., 1999; Moore et al., 
1998; Shanu et al., 2013). Of particular interest was the occurrence of a 
class of oxidized lipids termed isoprostanes formed from the hydrocar-
bon chains of membrane phospholipids in the glomerular membrane. 
Indeed, these oxidzed hydrocarbon chains were also found in the 
membrane still attached to the phoso head group proving that they were 
produced in situ in the kidney and had not been formed elsewhere and 
excreted through the kidney (Moore et al., 1998). The isoprostane 
formed from arachidonic chains, termed F2isoprostane, is a molecule 
with potent vasoconstrictive properties (Fukunaga et al., 1993; Morrow 
et al., 1992) and the discovery of this in the kidney prompted the pro-
posal that the formation of this through the peroxidatic action of Fe(III) 
Mb is responsible for blood flow restriction and hence kidney failure 
(Moore et al., 1998). This hypothesis has been strengthened through 
further studies carried out in vitro in which the oxidation of lipids, 
catalyzed by Mb, was followed through conjugated diene formation or 
through singlet oxygen production (Flors et al., 2006; Reeder, 2010). 
These studies elucidated a complex mechanism initiated by H2O2 or 
lipid peroxide and thereafter propagates through a radical chain reac-
tion (a simplified version of which is given in Fig. 2). This mechanism 
involves a catalytic redox cycle between Fe(III) and FeIV–O. Such a 
cascade of isoprostane formation, it may be appreciated, would severely 
restrict blood flow through the capillaries of the glomerulus and there-
fore have a very deleterious effect on kidney function. Furthermore, 
Reeder et al. have shown that X-linked Mb is considerably more 
pro-oxidant than native Mb potentially making the situation worse 
(Reeder and Wilson, 2005a). The peroxidatic activity of Mb is strongly 
enhanced at lower pH values, an effect we propose to arise from direct 
protonation of the ferryl species to generate the highly oxidizing 
FeIV–OH− (FeIIIOH●) species (see above) (Reeder et al., 2002b; Sila-
ghi-Dumitrescu et al., 2007). Thus, once Mb has entered the post 
glomerular space a vicious cycle is established in which isoprostanes are 
formed that restrict blood flow, this in turn leads to anaerobiosis of the 
tissue and the production of lactic acid that then lowers the pH which 
itself now enhances the catalytic activity of Mb. This is illustrated in 
Fig. 2. 
It is relevant in this context to note that one of the first and most 
common medical interventions following rhabdomyolysis is infusion 
with bicarbonate solutions (Better and Stein, 1990; Zager, 1989). We 
suggest that this procedure elevates the post-glomerular pH and thus 
lowers the fraction of protonated oxoferryl and renders FeIIIMb less 
harmful and protects the kidney (Moore et al., 1998; Silaghi-Dumitrescu 
et al., 2007). 
A similar oxidative mechanism has also been associated with Hb. 
Examination of cerebral spinal fluid from patients who have suffered 
subarachnoid hemorrhage reveals that a fraction of the Hb, freed from 
the protective antioxidant system of the erythrocyte through lysis of 
these cells in the cerebral fluid, have heme covalently bound to the α and 
β chains (Reeder et al., 2002a). Again in vitro studies have demonstrated 
that this bond is formed through the reaction of the ferric heme with 
peroxides (Reeder and Wilson, 2005b). There is another strong parallel 
between what happens in the kidney and what happens in the cerebral 
spinal fluid, namely, in the CSF lipid oxidation yields potent vasocon-
strictors, the neuroprostanes, analogous to the isoprostanes found in the 
kidney. It has been proposed that the neuroprostanes are responsible for 
the delayed vasospasm that follows hemorrhage and which is the sec-
ondary cause of fatality following hemorrhage (Corcoran et al., 2011; 
Hsieh et al., 2009). 
3. Strategies to intervene in the peroxidatic activity of Mb and 
Hb 
From the above account it may be appreciated that major patho-
logical events can follow the escape of Mb or Hb from their cellular 
environments and migration into spaces where antioxidant defenses are 
insufficient to protect against peroxidatic activity. Central to this ac-
tivity is the redox cycle in which the FeIIIMb/Hb, formed by auto 
oxidation of the oxy forms or from macrophage activity, reacts with 
H2O2 to form the ferryl species. This latter is returned to the ferric form 
by oxidizing biomolecules in the vicinity e.g. protein (forming the cross- 
linked biomarker) or lipid (forming the isoprostanes and neuro-
prostanes). This catalytic cycle may be short circuited by the addition of 
reductants that react with the ferryl species, generating the ferric form 
or potentially the physiologically active ferrous form, before it has time 
to oxidize lipids. 
In order to intervene medically in this catalytic cycle, it is essential to 
find efficient and safe reductants. Reeder et al. have studied the mech-
anism of reduction of ferryl Mb and Hb using a wide range of reductants 
and have demonstrated that all reductants so far examined transfer 
electrons to the ferryl heme through two quite separate pathways 
(Reeder et al., 2008a, 2008b, 2008c). These are: 1) Through the heme 
edge that is partially exposed to the reductant approaching from the 
bulk solution and 2) through a surface tyrosine residue that acts as a 
quasi-redox cofactor, accepting an electron from the reductant and 
donating it to the ferryl heme. As there are two independent sites each 
reacting with the reductant, one might expect that the time courses 
would reflect this by exhibiting two exponential phases. In fact, this 
need not necessarily be so. If at all times throughout the reaction the 
binding reactions are at equilibrium, meaning that the association and 
dissociation rate constants for binding are much faster than the electron 
transfer rate constants, then all the ferryl species are reduced to the 
ferric state together and follow a single exponential time course. The 
single rate constant for reduction of the ferryl species, kobs, does, how-
ever, carry the information that two processes are involved. The 
dependence of kobs on reductant concentration follows the sum of two 
hyperbolae reflecting the two hyperbolic binding processes. 
The evidence for these pathways is provided in Fig. 3A in which the 
time course for the reduction of sperm whale ferryl Mb is shown at a 
Fig. 2. Scheme showing the basic mechanism of ferric-ferryl redox cycling in 
lipid-based oxidative damage. Ferryl heme iron (and also protein-based radi-
cals) can oxidize lipid membranes to initiate formation of a series of iso-
prostanes (15-F2 Iso-P shown) with similar vasoactive properties to 
prostaglandins. Often resulting in acidosis due to the reduced supply of oxygen 
to the tissue, the lowered pH enhances and amplifies lipid oxidation in a vi-
cious cycle. 
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number of reductant concentrations. Here the reductant CP20 (1,2- 
dimethyl-3-hydroxypyrid-4-one) known commercially as deferiprone, it 
is both a reductant and an iron chelator given orally to remove iron in 
cases of iron overload e.g. following blood transfusions for Thalassemia 
(Hoffbrand, 1995; Zanninelli et al., 1997). These time courses fit well to 
single exponentials for Mb (Reeder et al., 2008a, 2008c) and double 
exponentials for Hb (Reeder et al., 2008b). The rate constant for 
reduction given by these fits increase with increasing reductant con-
centration and this dependency is shown in Fig. 3B. These data can be 
fitted as the sum of two hyperbolic curves (Reeder et al., 2008b). A full 
mechanistic analysis reported by Reeder et al. (2008a) demonstrates that 
this behavior is expected if the reductant can bind at two independent 
sites on the protein and each site can donate an electron to the ferryl 
heme (Reeder et al., 2008a, 2008b; Silkstone et al., 2016a, 2016b). This 
analysis allows the assignment of KD values (equilibrium dissociation 
constants for the binding reaction) to the sites and rate constant for the 
electron transfer rate within the reductant/protein complex. 
Substituting Tyr103 for a Phe in sperm whale Mb abolishes the high 
affinity site leaving the lower affinity site still operational (see Fig. 3B), 
indicating that this residue (~5A from the heme) acts as part of a 
through-protein electron transfer pathway. The behavior shown in Fig. 3 
is essentially the same for all reductants so far examined. 
Furthermore, for a given protein the maximum electron transfer rate 
constant for the high affinity site is the same for all reductants con-
firming that once the site is fully occupied by the reductant the electron 
transfer rate constant depends on the nature of the protein and not the 
reductant. The affinity for this site for reductants does, however, depend 
on the nature of the reductant as may be expected, as binding involves 
specific interactions between the reductant and the protein. This 
behavior is illustrated in Table 1 where it is seen that for Equine Mb the 
maximum rate constant (kmax1) remains ~0,01s− 1 irrespective of the 
chemical nature of the reductant used while the values of KD vary 
widely. 
Electron transfer through the second lower affinity site is also 
strongly affected by the size, shape and charge of the reductant, because 
the reductant must partially enter the heme crevice to access the heme 
edge prior to electron transfer (Reeder et al., 2008a). The two pathways 
are illustrated schematically in Fig. 4. 
Fig. 3. (A) CP20 acts as a reductant for ferryl myoglobin (sperm whale), similar 
to urate and ascorbate, reducing the protein to the ferric oxidation state. (B) 
The kinetic profile of the reduction of ferryl myoglobin by CP20 (circles). The 
profile is fitted to a two hyperbola representing the two possible electron 
pathways. The through-protein pathway can be eliminated through mutation of 
the myoglobin to remove a redox active tyrosine between the heme iron and 
external environment (Tyr103 to Phe, squares). 
Table 1 
Values for dissociation constant (KD) and rate constant maxima for the high- 
affinity site for iron chelators and related compounds and reductants at pH 
7.4. Values for KD1 and kmax1 were calculated from the fitting kinetic data to a 
double rectangular hyperbola function. ND denotes not determined as the time 
courses of the high and low-affinity electron transfer pathway could not be 
separated. “—” denotes no high affinity pathway as the protein contains no 
tyrosine residues. CP02 (1-ethyl-3-hydroxypyrid-2-one), CP20 (1,2-dimethyl-3- 
hydroxypyrid-4-one), CP358 (1,6-dimethyl-2-(N-4’,N-propylsuccinamido) 
methyl-3-hyrdoxypyridin-4-one).  
Myoglobin Compound KD1 (μM) kmax1 (s− 1) 
Equine CP02 9.7 0.96 × 10− 2 
CP20 110 1.17 × 10− 2 
CP358 330 1.19 × 10− 2 
Maltol 74 1.27 × 10− 2 
8-Hydroxyquinoline 47 1.15 × 10− 2 
1-Hydroxypyridine 2-one ND ND 
Hydroxyurea 340 1.25 × 10− 2 
p-Cresol ND ND 
Phenol ND ND 
Ascorbate 0.8 1.20 × 10− 2 
CP20 (V63H) – – 
Aplysia CP20 (V63H/F42Y) 26 4.47 × 10− 1 
CP20 (V63H/F98Y) 446 4.30  
Fig. 4. Two site model for reduction of ferryl globin. Through-protein electron 
transfer via redox active tyrosine (top left panel) results in a high affinity 
pathway enhancing ferryl reduction at low concentrations of reductant (lower 
panel circled in green). Direct access to the heme pocket (top right panel) re-
sults in a lower affinity electron pathway (lower panel circled in red). (For 
interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
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To confirm the conclusions drawn above regarding the role of surface 
tyrosines in ferryl heme reduction the Mb from Aplysia faciata (sea hare) 
was studied (Reeder et al., 2012; Svistunenko et al., 2007). This protein 
has no Tyr residues but has 15 phenylalanines (Fig. 5). By substituting 
Tyr residues for specific Phe residues one is, therefore, able to insert a 
Tyr residues at selected positions and thereby construct a putative 
electron transfer pathway where one did not exist before. There are two 
Phe residues (Phe 41 and 98) close to the heme and when either of these 
is substituted by a Tyr the rate constant for ferryl heme reduction is 
greatly enhanced. For example, for the F98Y variant the increase is 1200 
fold with ascorbate as reductant and 1600 fold with deferiprone as 
reductant (Reeder et al., 2012). In Table 1 it is seen that for Aplysia Mb 
where no Tyr residues are present no through protein electron transfer 
occurs but on insertion of Tyr residues the pathway is evident, and the 
position of the residue dictates the kmax1 and KD values. 
These results cannot be explained in terms of changes in the donor 
acceptor distance or redox potential but shows that the Tyr residue must 
act as a redox co-factor by virtue of the fact that the aromatic phenolic 
moiety can harbor a radical. The mechanistic details of how Tyr forms a 
radical by donating an electron to the ferryl heme have been discussed 
by Reeder et al. and these authors propose that the reason that this 
electron transfer appears to be so slow in comparison with expectation 
based on the Marcus theory is because electron transfer can only occur in 
a small fraction of the protein (10− 7 of the total), that has both pro-
tonated oxyferryl and deprotonated tyrosine (Reeder et al., 2012). Rapid 
protonation equilibration ensures that all the protein flows through this 
species and thus all the oxoferryl form is reduced but at a rate 107 fold 
slower than if all the protein could participate in Tyr to heme electron 
transfer. 
The donation of electrons from an exogenous reductant through the 
Tyr residue to the heme has also been shown to inhibit lipid peroxidation 
and formation of the heme to protein cross-link. These observations will 
be further discussed and illustrated below. 
From the above several conclusions may be drawn that are useful 
when considering heme induced oxidative damage in vivo and how to 
develop therapeutic strategies to intervene and limit these processes. 
These are:  
1) Mb and Hb, once outside their cells and in spaces unprotected by 
cellular defense systems, e.g. post glomerular space, CFS, synovial 
fluid, are toxic. This stems from the formation of ferryl heme that can 
oxidize lipids to form molecules with powerful vasoconstrictive 
properties. A unique biomarker for this activity is the formation of 
heme to protein covalent bonds.  
2) The ferric/ferryl cycle, fueled by peroxides may be prevented from 
oxidizing lipids by the addition of a wide range of reductant, e.g. 
ascorbate. Many of these are safe to take either orally or by infusion 
and therefore may offer therapeutic opportunities.  
3) A wide range of molecules developed to act as iron chelators in vivo 
(e.g. hydroxypyridones, desferrioxamine,etc) also act as ferryl re-
ductants. This is an important point to emphasize as it means that 
amelioration of the effects of frequent transfusions for patients with 
thalassemia can be through the mechanism of ferryl reduction of the 
heme and not solely due to iron chelation following heme degrada-
tion by heme oxygenase.  
4) Reduction, at low reductant concentrations, is essentially through 
the pathway involving surface Tyr. This is important to recognize as 
it informs the design of Hb based blood substitutes (Hb based oxygen 
carriers, HBOCs), see below. 
4. Therapeutic intervention in rhabdomyolysis 
Acetaminophen, Ac, is a mild painkiller available without prescrip-
tion in most countries. Depending on the country and the formulation 
this compound goes under any of over one hundred brand names e.g. 
Paracetamol, Panadol, Tylenol etc. It has been reported that Ac inhibits 
prostaglandin H2 synthases by reducing the oxoferryl porphyrin radical 
in the enzyme that is essential for the oxygenation of arachidonic acid 
(Anderson, 2008; Aronoff et al., 2006). As mentioned above it is known 
that Mb similarly oxidizes arachidonic acid in the presence of H2O2 and 
Boutaud et al. reported that this reaction was also inhibited by Ac and 
that Ac can donate electrons to the ferryl species through both the 
through-protein, Tyr route, and the heme edge pathway. These in vitro 
results suggest that Ac may possibly act similarly in vivo and offer a 
simple, safe and cheap way to ameliorate the deleterious effects of 
rhabdomyolysis. This hypothesis has been tested by Boutaud et al. in a 
rat model of rhabdomyolysis (Boutaud et al., 2010). The results of this 
study in which control animals, rhabdomyolyic animals and rhabdo-
myolytic animals with Ac administered (400 mg/kg) were compared 
proved very encouraging. All measures of oxidative stress reactions, 
Fig. 5. Aplysia myoglobin exhibits extensive enhancement of the ferryl reduction kinetics by reductants upon selected tyrosine mutations. Left: Crystal structure of 
myoglobin from Aplysia faciata (Aplysia limacina as a junior synonym). PDB code 1MBA, this wild type protein was mutated (V63H, F42Y and F98Y) in silico. This 
protein has 15 phenylalanine residues close to the heme iron that can be selectively mutated to redox active tyrosine residues. Right: The V63H variant (green) was 
used to provide a distal histidine present in most human globins. V63H/F42Y (purple) and V63H/F98Y (blue) mutations exhibits significantly enhanced kinetics of 
ferryl reduction by low micromolar levels of reductants (50 μM Ascorbate shown). (For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
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much elevated in the rhabdomyolytic animals, were brought closer to 
values seen in the controls by administration of Ac. Treatment using Ac 
reduces both urinary and plasma F2 isoprostanes, reduces creatine 
plasma levels and enhances creatinine clearance. In addition, the 
biomarker, cross-linked Mb, in the urine was greatly decreased. All these 
parameters indicate that Ac administration leads to less kidney damage 
and improved kidney function. Furthermore, visual inspection of kid-
neys, removed postmortem, revealed that while the rhabdomyolytic rat 
kidney was strongly discolored that from the treated rats had a relatively 
normal aspect. 
These results indicate Ac or other compound that can target the 
oxyferryl species may offer a useful additional treatment for human 
patients. 
5. Strategies for designing hemoglobin based oxygen carriers 
(HBOC’s) 
Blood transfusions are lifesaving interventions in many serious 
medical conditions including trauma, surgery, thalassemia etc. The 
blood for these transfusions is given, either freely or for a fee, by human 
donors. Inherent to this process are a number of problems that must be 
overcome to ensure the safety of the patient receiving the blood. The 
major one of these is that donated blood may be contaminated with 
viruses, e.g. HIV, hepatitis etc and new blood borne viruses are being 
found at the rate of at least two per year. For developed countries, the 
risk of such contamination can be essentially removed through screening 
but in poorer countries this is often not possible and indeed even testing 
the blood for viruses may not be routinely undertaken. Once the blood 
has been taken, erythrocytes must be stored in a refrigerator and have a 
life span of some 42 days (FDA regulation). However, biochemical and 
morphological changes to the stored erythrocytes suggest that older 
blood has adverse biological characteristics in critically ill patients, 
although studies thus far are far from conclusive (Bennett-Guerrero 
et al., 2007). In the United Kingdom, the maximum erythrocyte storage 
time is set at 35 days. These problems, together with the need for 
blood-typing and the expense of running an efficient, safe transfusion 
service, have driven the search for alternatives. The ideal would be an 
oxygen carrying therapeutic that is virus free, has no requirement for 
immunity typing, is easily stored and has a long shelf life. One possibility 
that has been explored is an Hb based -oxygen carrier (HBOC), using 
human or animal Hb (or its engineered variants). Classically such 
HBOCs are generated from chemical modifications of Hb purified from 
out-of-date human or animal blood. However, more recently, recombi-
nant Hbs purified from transformed E coli are being developed. Such 
‘artificial’ blood could solve the problems of compatibility, storage, vi-
ruses etc. Although having large quantities of virus-free HbA is a 
necessary requirement for producing a therapeutic oxygen carrier for 
human use, there is a number of other problems that must be solved 
before it could fulfil this role. In solution the tetramers of Hb can 
dissociate into αβ dimers that can pass through the kidney and thereby 
lead to organ failure (see above). To prevent this, tetramers can be 
stabilized either through chemical crosslinking at the dimer-dimer 
interface or by mutation. Furthermore, the tetramers themselves may 
be either encapsulated or joined together and decorated with poly-
ethylene glycol (PEG) chains, which ensures that the crosslinked Hb 
remains within the vasculature. Crosslinking and PEGylation also reduce 
the osmotic pressure of the preparation and reduce its immunogenicity. 
Despite these advances and the many years during which satisfactory 
HBOCs have been sought, clinical trials have not led to any product 
securing regulatory approval for general human use, although use in 
specific critical medical situations they have been used for individuals 
(Nellis et al., 2020). The reasons why HBOCs have not been approved 
and found wider use are complex and have been extensively discussed 
by Alayash (Alayash, 2014, 2019; Buehler and Alayash, 2008) and by 
Olson (Benitez Cardenas et al., 2019; Varnado et al., 2013) and will not 
be further discussed here, except to draw attention to two important 
factors. The first of these is that HBOCs, unlike erythrocytes, may closely 
approach the epithelial surface lining the capillaries and remove NO, 
produced by the epithelium, either by binding it or by converting it to 
nitrate. As NO is a potent relaxant of the vascular muscle tone this results 
in elevated blood pressure. The second is related to oxidative damage as 
discussed above. The use of recombinant technology provides an op-
portunity to address both the issue of NO scavenging and of oxidative 
damage through selected mutation of the Hb. Recombinant Hb also al-
lows mutations to enhance protein stability (Varnado et al., 2013) or the 
use of other Hbs such as the more inherently stable fetal Hb (HbF 
(Chakane et al., 2017; Ratanasopa et al., 2016; Simons et al., 2018). 
Olson et al., through specific site mutations of the heme cavity, have 
successfully produced HBOCs with lower NO reactivities (Benitez Car-
denas et al., 2019). The first attempt at a commercial recombinant 
HBOC, rHb2.0, developed by Somatogen (later Baxter Healthcare) spe-
cifically focused on combating the intrinsically rapid NO scavenging 
capability of Hb (Burhop, 2005; Raat et al., 2005). This entered clinical 
trials, but was discontinued due to adverse side reactions triggered by 
extracellular Hb (Varnado et al., 2013). Therefore, NO scavenging seems 
not to be the sole reason for adverse effects such as elevated blood 
pressure. The second important factor we suggest is the peroxidatic 
activity of the heme that, as in the kidney and CFS, generates vasocon-
strictive oxidize lipids that act on the arteries and capillary bed. In 
addition, Alayash and coworkers have shown that the radical formed on 
HBA, as a consequence of the reaction between ferric Hb and H2O2 (Eq 
(2)), may preferentially migrate to a cysteine residue (β93) and irre-
versibly oxidize this to cysteic acid. This oxidation process accumulate 
throughout blood storage and has major effects on Hb stability and is a 
major cause of aging of the red blood cell during storage (Alayash, 
2021). 
To address the intrinsic oxidative toxicity of HBOCs the group at 
Essex have engineered an HBOC that suppresses the oxidative activity of 
Hb in the presence of low concentrations of reductants. In WT human 
HbA the α chains possess a surface tyrosine (Tyr 42) that can act as a 
conduit for electron transfer to the heme while the β chains (or the γ 
chains of HbF) do not possess a suitably located Tyr but have a Phe (Phe 
41) close to the heme. If this is substituted by a Tyr a new electron 
pathway is formed and ferryl heme in the β/γ chains is, as the α chains, 
reduced more rapidly and at lower reductant concentrations and is also 
less active as a lipid peroxidase under these conditions. These encour-
aging results have led to the β Phe41Tyr variant, or other Tyr variants, to 
be platforms from which to develop a new generation of HBOCs (Cooper 
et al., 2019; Silkstone et al., 2016a, 2016b, 2018), see Fig. 6. An addi-
tional effect of some Tyr variants is an enhancement of the ferric to 
ferrous reduction, more rapidly returning the protein from its inactive 
ferric form to the physiologically active oxygen carrying ferrous form 
(Silkstone et al., 2018). 
Besides encapsulation and polymerization, which deserve their own 
extended review, PEGylation is one of the preferred strategies to keep 
the HBOC in the vasculature, preventing rapid renal clearance and hence 
decrease renal damage. PEGylation has been used in a variety of prod-
ucts in clinical trials (Abuchowski, 2017; Vandegriff and Winslow, 2009; 
Vincent et al., 2015). However, PEGylation using standard reactive 
agents such as maleimide-PEG typically generates highly heterogeneous 
mixtures that disrupt oxygen binding affinity and cooperatively. The use 
of recombinant HBOCs allows specific sites to be engineered that do not 
modify protein functionality and creates a much more homogeneous 
product (Cooper et al., 2020). Current research combining the strategies 
of using recombinant Hb to combine Hb stability, decreased NO scav-
enging, decreased oxidative damage and homogeneous PEGylation is 
ongoing at Essex. 
The work over the past couple of decades has led to a much better 
understanding of globin toxicity. It is well established that release of Hb 
or Mb from the protective environment of the erythrocyte or myocyte 
leads to pathological consequences for a variety of reasons. An impor-
tant one is the peroxidatic activity of these proteins. Above we have 
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addressed some examples of these such as rhabdomyolysis associated 
acute kidney injury, delayed vasospasm following subarachnoid hem-
orrhage and hemoglobin-based blood substitutes. However, this list is 
far from complete and there are many other conditions in which Mb and 
Hb, lysed from cells, may be involved in pathological processes. Exam-
ples of these include hemolytic anaemias (such as sickle cell) and snake 
bite (e.g. Russel’s viper), the latter causing severe lysis of erythrocytes 
and is a significant cause of death in Asia. One might seek interventions 
for these conditions through administration of suitable reductants to 
remove cytotoxic ferryl and associated radical species and research to 
this end is ongoing. 
A short review, such as this, cannot hope to cover adequately all the 
medical consequences of Mb and Hb acting as peroxidases. However, 
this brief survey of some major pathologies may serve to illustrate the 
wide-ranging repercussions of freeing Mb and Hb from their cellular 
environments. The fundamental chemical reaction between heme and 
H2O2, to generate ferryl heme and radicals, we suggest, has wide- 
ranging ramifications and is the underlying contributing cause of 
many severe pathological conditions. 
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